Clinical trials: Drug Relapse
Plasma Cell Myeloma
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended…
- Trial name
- NCT04000282
- Testing
- SAR442085
- Where
- 12 sites in United States, Czechia and 4 more
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Sanofi
Positron-Emission Tomography, Multiple Sclerosis
Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8101 for investigation in patients with Multiple Sclerosis compared to healthy volunteers
- Trial name
- NCT01031199
- Testing
- F-18 FEDAA1106 (BAY85-8101)
- Where
- 2 sites in Australia, Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis
Avonex 15 Year Long Term Follow-up Study
The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients…
- Trial name
- 15yASSURANCE (NCT00525343)
- Where
- 4 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Biogen
Relapsed or Refractory Lymphoma
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
- Trial name
- NCT05602597
- Testing
- Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Hutchmed